纖溶酶原激活物抑制因子1(PAI1)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Plasminogen Activator Inhibitor 1 (PAI1) ,etc. by FLIA (Flow Luminescence Immunoassay)
SERPINE1; PLANH1; Serpin Peptidase Inhibitor Clade E Member 1; Nexin,Plasminogen Activator Inhibitor Type 1 Serpin E1; Endothelial plasminogen activator inhibitor
（注：單次混測多因子不超過8個指標 ）
- 編號ULMA532Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 實驗方法雙抗夾心
- 反應(yīng)時長3.5h
- 檢測范圍0.02-20ng/mL
- 靈敏度最小可檢測劑量小于等于0.007 ng/mL.
- 樣本類型Plasma
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標數(shù) 7指標數(shù) 6指標數(shù) 5指標數(shù) 4指標數(shù) 3指標數(shù) 2指標數(shù)1指標數(shù)
- 價格 ¥ 1281 ¥ 1330 ¥ 1404 ¥ 1502 ¥ 1601 ¥ 1749 ¥ 1970 ¥ 2463 添加到價格計算器 計算器
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
本試劑盒用于檢測纖溶酶原激活物抑制因子1(PAI1)等多因子檢測試劑盒(流式熒光發(fā)光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的纖溶酶原激活物抑制因子1(PAI1)等多因子檢測試劑盒(流式熒光發(fā)光法)（加標樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 93-105 | 97 |
| EDTA plasma(n=5) | 78-96 | 83 |
| heparin plasma(n=5) | 91-99 | 95 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的纖溶酶原激活物抑制因子1(PAI1)等多因子檢測試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中纖溶酶原激活物抑制因子1(PAI1)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 81-96% | 95-105% | 81-99% | 93-104% |
| EDTA plasma(n=5) | 93-101% | 95-102% | 80-97% | 90-104% |
| heparin plasma(n=5) | 91-105% | 80-104% | 84-96% | 79-97% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本準備；
2. 加樣（標準品、樣本、磁珠）標準品或樣本100μL及磁珠10μL，
37°C酶標板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測溶液A100μL，37°C酶標板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測溶液B100μL，37°C振動孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實驗原理
將纖溶酶原激活物抑制因子1(PAI1)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標準品或標本以及磁珠，其中的纖溶酶原激活物抑制因子1(PAI1)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的纖溶酶原激活物抑制因子1(PAI1)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標記的親和素，再次徹底洗滌后即可上機讀數(shù)。MFI值和樣品中的纖溶酶原激活物抑制因子1(PAI1)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA532Ra01 | 纖溶酶原激活物抑制因子1(PAI1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA532Ra01 | 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體 | WB; IHC |
| UMAA532Ra21 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
| USEA532Ra | 纖溶酶原激活物抑制因子1(PAI1)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCA532Ra | 纖溶酶原激活物抑制因子1(PAI1)檢測試劑盒(化學發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMA532Ra | 纖溶酶原激活物抑制因子1(PAI1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSA532Ra01 | 纖溶酶原激活物抑制因子1(PAI1)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Breast Cancer Research and Treatment | Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice [SpringerLink: f3w831267267p277] |
| Clin Appl Thromb Hemost. | Is There Any Association Between Thrombosis and Tissue Factor Pathway Inhibitor Levels in Patients With Vitamin D Deficiency? [Pubmed: 24203351] |
| Molecular Nutrition & Food Research | Trans‐fatty acid promotes thrombus formation in mice by aggravating antithrombogenic endothelial functions via Toll‐like receptors [PubMed: 25546502] |
| Archives of Physiology and Biochemistry | Activation of cardiac renin–angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder [Pubmed:26934364] |
| Naunyn-Schmiedeberg's Archives of Pharmacology | Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression [pubmed:27447455] |
| Environmental toxicology and pharmacology | Combined oral contraceptive and nitric oxide synthesis inhibition synergistically causes cardiac hypertrophy and exacerbates insulin resistance in female rats. [pubmed:28376377] |
| Annals of Clinical & Laboratory Science | Alteration of Hemostatic Parameters in Patients with Different Levels of Subclinical Hypothyroidism and the Effect of L-thyroxine Treatment [pubmed:28249913] |
| Pharmacological reports | Anti-inflammatory and antithrombotic effects of nicotine exposure in oral contraceptive-induced insulin resistance are glucocorticoid-independent [pubmed:28349880] |
| Haematologica | Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domain [Pubmed:29903766] |
| Biomedicine & Pharmacotherapy | Puerarin prevents vascular endothelial injury through suppression of NF-κB activation in LPS-challenged human umbilical vein endothelial cells [Pubmed:29775893] |
| Archives of?Physical?Medicine?and Rehabilitation | Impact of Regular Physical Activity on Adipocytokines and Cardiovascular Characteristics in Spinal Cord–Injured Subjects [Pubmed:29548578] |
| Marine Drugs | Anticoagulant and Antithrombotic Properties in Vitro and in Vivo of a Novel Sulfated Polysaccharide from Marine Green Alga Monostroma nitidum [Pubmed: 31027312] |
| Experimental and Therapeutic Medicine | IKKβ regulates the expression of coagulation and fibrinolysis factors through the NF?κB canonical pathway in LPS?stimulated alveolar epithelial cells type II [Pubmed: 31572531] |
| Phytomedicine | Sodium aescinate significantly suppress postoperative peritoneal adhesion by inhibiting the RhoA/ROCK signaling pathway [Pubmed: 32120245] |
| Sci Rep | Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis [Pubmed:35013379] |
| Phytomedicine | Multi-omics analysis reveals the mechanisms of action and therapeutic regimens of traditional Chinese medicine, Bufei Jianpi granules: Implication for COPD drug?… [Pubmed:35121390] |
